Therapy of metastatic renal cell carcinoma (mRCC) with targeted inhibitors of key cellular processes is a relative new option for systemic treatment. Its optimum use requires, among others, a thorough analysis of the results obtained in routine clinical practice.
These data for the Czech Republic are collected in the RENIS database.